Compare Brookfield Infrastructure Partners LP (BIP) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs IDEXX Laboratories, Inc. — how do they compare? Brookfield Infrastructure Partners LP trades at $38.97 (market cap $17.38B), while IDEXX Laboratories, Inc. trades at $565.3 (market cap $42.65B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.5× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays a 4.77% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| BIP | IDXX | |
|---|---|---|
Market Cap | $17.38B | $42.65B |
Sector | Industrials | Health |
52-Week High | $40.08 | $766.68 |
52-Week Low | $29.81 | $514.61 |
Enterprise Value | $79.06B | $43.56B |
Dividend Yield | 4.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $37.61, down slightly by 0.11% today. The stock shows bullish technical signals with strong analyst support (81% buy ratings) and a $45.50 consensus price target. Recent earnings have been mixed with one beat and two misses, but the company maintains robust cash flows with $5.97B from operations in 2025. BIP offers a 5% dividend yield with recent H1-26 payment of $0.46 per share.
BIP presents a compelling value opportunity with discounted valuation metrics (P/S 0.73, EV/EBITDA 7.55) and strong infrastructure assets. However, investors face risks from recent earnings volatility, high P/E ratio of 57.8, and declining profit margins. The company's global infrastructure portfolio provides inflation protection and stable cash flows, supporting the bullish analyst consensus despite near-term headwinds.
IDXX trades at $564.09, up 0.09% with neutral technical signals. The stock shows strong fundamentals with revenue growth to $4.3B in 2025 and consistent earnings beats. Analyst consensus is bullish (59% Buy) with improving cash flow trends. Recent news highlights AI integration in medical devices and upcoming Q2 2026 earnings.
Outlook remains positive driven by innovation and market leadership in pet healthcare. Risks include high valuation multiples and competitive pressures. Institutional sentiment supports growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
